BioMarin Pharmaceutical Inc (BMRN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jean-Jacques Bienaimé
Employees:
3,040
105 DIGITAL DRIVE, NOVATO, CA 94949
4155066700

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Data derived from most recent annual or quarterly report
Market Cap 17.76 Billion Shares Outstanding184.995 Million Avg 30-day Volume 1.08 Million
P/E Ratio287.2908 Dividend Yield0.0 EPS4.33
Price to Revenue8.1256 Debt to Equity0.2466 EBITDA179.7 Million
Price to Book Value3.4483 Operating Margin3.0015 Enterprise Value15.123 Billion
Current Ratio5.417 EPS Growth-0.939 Quick Ratio3.392
1 Yr BETA 0.8619 52-week High/Low 97.76 / 70.73 Profit Margin2.8284
Operating Cash Flow Growth-55.7685 Altman Z-Score6.2486 Free Cash Flow to Firm -161.196 Million
Earnings Report2022-10-26
View SEC Filings from BMRN instead.

View recent insider trading info

Funds Holding BMRN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BMRN

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-31:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-04-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-23:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-11-03:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-10-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-02:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2021-06-01:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    24.4 Thousand total shares from 4 transactions

    Exercise Derivative Conversion (M)

    3.5 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GUYER CHARLES GREG EVP, CHIEF TECHNICAL OFFICER

    • Officer
    42,168 2022-08-08 4

    MUELLER BRIAN EVP, CHIEF FINANCIAL OFFICER

    • Officer
    37,987 2022-08-05 6

    DAVIS GEORGE ERIC EVP, CHIEF LEGAL OFFICER

    • Officer
    58,941 2022-07-08 6

    AJER JEFFREY ROBERT EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    47,088 2022-06-03 7

    PYOTT DAVID E I

    • Director
    40,840 2022-05-24 1

    MEIER RICHARD A

    • Director
    108,994 2022-05-24 2

    HERON ELAINE J

    • Director
    85,568 2022-05-24 2

    LAWLIS V BRYAN

    • Director
    28,950 2022-05-24 3

    DERE WILLARD H

    • Director
    23,390 2022-05-24 1

    HOMBACH ROBERT J.

    • Director
    26,310 2022-05-24 1

    ALLES MARK J

    • Director
    7,280 2022-05-24 3

    SLAMON DENNIS

    • Director
    26,619 2022-05-24 2

    HO MAYKIN

    • Director
    12,450 2022-05-24 1

    ANDERSON ELIZABETH M

    • Director
    18,890 2022-05-24 1

    BURKHART ERIN GVP, CHIEF ACCOUNTING OFFICER

    • Officer
    28,620 2022-05-16 2

    BIENAIME JEAN JACQUES CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    1,273,505 2022-04-29 11

    FUCHS HENRY J PRESIDENT, WORLDWIDE R&D

    • Officer
    325,595 2022-03-15 3

    ACOSTA ANDREA GVP, CHIEF ACCOUNTING OFFICER

    • Officer
    18,122 2021-04-30 0

    GREY MICHAEL G

    • Director
    42,840 2021-03-05 0

    BAFFI ROBERT PRESIDENT, GLOBAL MFG/TECH OPS

    • Officer
    189,020 2020-03-20 0

    LEWIS ALAN

    • Director
    25,590 2019-06-04 0

    SPIEGELMAN DANIEL K EVP, CHIEF FINANCIAL OFFICER

    • Officer
    47,686 2019-04-30 0

    FALBERG KATHRYN E

    • Director
    3,300 2016-07-15 0

    LAPALME PIERRE

    • Director
    32,750 2015-06-10 0

    BATE KENNETH

    • Director
    11,875 2015-06-10 0

    YOUNG WILLIAM D

    • Director
    11,875 2015-06-10 0

    WOOD MARK VP, HUMAN RESOURCES

    • Officer
    20,277 2013-05-22 0

    ASELAGE STEVE EVP, CHIEF BUSINESS OFFICER

    • Officer
    59,030 2012-07-02 0

    COOPER JEFFREY H SVP, CHIEF FINANCIAL OFFICER

    • Officer
    41,089 2012-04-30 0

    KLEIN JOSEPH III

    • Director
    35,000 2010-03-08 0

    KAKKIS EMIL D CHIEF MEDICAL OFFICER

    • Officer
    44,275 2009-03-02 0

    SWIEDLER STUART J SVP, CLINICAL AFFAIRS

    • Officer
    No longer subject to file 2008-07-07 0

    CRISTIANI FRANZ L

    • Director
    135,000 2006-06-14 0

    SAGER ERICH

    • Director
    197,444 2006-02-24 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    GUYER CHARLES GREG - Officer EVP, CHIEF TECHNICAL OFFICER

    2022-08-10 19:52:23 -0400 2022-08-08 S 6,205 $96.56 d 42,168 direct

    MUELLER BRIAN - Officer EVP, CHIEF FINANCIAL OFFICER

    2022-08-09 19:27:40 -0400 2022-08-05 M 3,500 $67.81 a 34,226 direct

    MUELLER BRIAN - Officer EVP, CHIEF FINANCIAL OFFICER

    2022-08-09 19:27:40 -0400 2022-08-05 S 3,500 $94.50 d 30,726 direct

    MUELLER BRIAN - Officer EVP, CHIEF FINANCIAL OFFICER

    2022-08-09 19:27:40 -0400 2022-08-05 M 3,500 d 7,261 direct

    DAVIS GEORGE ERIC - Officer EVP, CHIEF LEGAL OFFICER

    2022-07-11 19:46:22 -0400 2022-07-08 S 7,398 $90.00 d 58,941 direct 0.296 -2.0034 0.296 2 -2.675 5

    MUELLER BRIAN - Officer EVP, CHIEF FINANCIAL OFFICER

    2022-07-12 14:25:43 -0400 2022-07-08 S 7,337 $89.50 d 30,726 direct 0.296 -2.0034 0.296 2 -2.675 5

    MUELLER BRIAN - Officer EVP, CHIEF FINANCIAL OFFICER

    2022-07-01 15:25:54 -0400 2022-06-29 F 576 $83.92 d 38,063 direct 1.6239 3.3537 4.7541 5 0.0 1

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 22:15:03 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 21:45:04 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 21:15:03 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 20:45:04 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 20:15:03 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 19:45:04 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 19:15:05 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 18:45:03 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 18:15:05 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 17:45:05 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 17:15:05 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 16:45:04 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 16:15:05 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 15:45:05 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 15:15:03 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 14:45:06 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 14:15:04 UTC 2.07 0.25 4100000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 13:45:04 UTC 2.07 0.25 4000000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 13:15:04 UTC 2.07 0.25 4000000
    BIOMARIN PHARMACEUTICAL INC BMRN 2022-08-11 12:45:04 UTC 2.07 0.25 4000000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    AGF Investments Trust- AGFIQ U.S. Market Neutral Momentum Fund BMRN -304.0 shares, $-26657.76 2020-12-31 N-PORT
    FundVantage Trust- Gotham Master Neutral Fund BMRN -16.0 shares, $-1217.28 2020-09-30 N-PORT
    Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund BMRN -900.0 shares, $-75096.0 2021-06-30 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund BMRN -2708.0 shares, $-208786.8 2022-03-31 N-PORT
    JNL Series Trust- JNL Multi-Manager Alternative Fund BMRN -230.0 shares, $-17733.0 2022-03-31 N-PORT
    AQR Funds- AQR Alternative Risk Premia Fund BMRN -653.0 shares, $-50346.3 2022-03-31 N-PORT
    LAZARD FUNDS INC- Lazard Enhanced Opportunities Portfolio BMRN -149.0 shares, $-11487.9 2022-03-31 N-PORT
    Principal Funds, Inc- Global Multi-Strategy Fund BMRN 3582.0 shares, $-269115.66 2022-05-31 N-PORT
    GMO TRUST- GMO Strategic Opportunities Allocation Fund BMRN -3400.0 shares, $-255442.0 2022-05-31 N-PORT
    GMO TRUST- GMO Benchmark-Free Fund BMRN -22600.0 shares, $-1697938.0 2022-05-31 N-PORT
    GMO TRUST- GMO Implementation Fund BMRN -69300.0 shares, $-5206509.0 2022-05-31 N-PORT
    GMO TRUST- GMO Alternative Allocation Fund BMRN -3900.0 shares, $-293007.0 2022-05-31 N-PORT

    Elevate your investments